Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

To join this study, you must be a man aged 18 or older with prostate cancer that has spread and has been confirmed by a doctor. Your cancer must also be responding to hormone therapy (meaning your testosterone levels are low due to treatment or surgery).

Doctors will also check your overall health using a scale called ECOG, and you'll need to be quite well to take part. Your body's organs, like your liver and kidneys, need to be working properly, and your blood counts should be healthy. You must also have evidence that your cancer has recently gotten worse, which can be seen by increases in your PSA blood test, new growths on scans, or new spots on bone scans.

There are also reasons why you might not be able to join. For example, if your cancer has spread to your brain or is pressing on your spinal cord, unless these issues are stable and don't require high doses of certain medications, you probably won't be eligible. The study team will review all your medical information carefully to see if this study is right for you.

If you join this study, you'll receive the study medicine, AZD0516 (either alone or with another drug, AZD9574), according to a plan set by the study team. You will have regular visits to the clinic for check-ups, blood tests, and scans to see how you are doing and how the medicine is affecting your body and the cancer. These visits will also help the doctors track any side effects. You'll continue to receive your standard hormone therapy (if you haven't had surgery to remove your testes) throughout the study. The total duration of your participation will depend on how you respond to the treatment and what the study doctors decide, but it will involve ongoing assessments and potentially follow-up after the treatment phase ends.